The Role of Biomarkers in Immunotherapy Selection for mUC

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.

Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.